A new algorithm identifies the patients that will most benefit from immunotherapy

Predictive decision trees optimized to decide if a cancer mutation will become visible to the immune system. Rik G.H. Lindeboom, Radboud University.

Predictive decision trees optimized to decide if a cancer mutation will become visible to the immune system. Rik G.H. Lindeboom, Radboud University.


RTVE, the newspaper Heraldo de Aragón, and Diario Médico—the newspaper specialized in health—among other media, have echoed on a new algorithm, developed by researchers at IRB Barcelona in collaboration with the Centre for Genomic Regulation and the University of Radboud, that allows identification of those patients who are most likely to benefit from immunotherapy. Based on machine learning, the scientists have developed a tool that detects the genetic mutations that activate the immune system. This algorithm also identifies those people with certain hereditary diseases that would benefit from certain kinds of drug already on the market. The study was published in the journal Nature Genetics.

 

 

Link to RTVE 

Link to Heraldo de Aragón 

Link to Diario Médico